Proteomic Studies of Cholangiocarcinoma and Hepatocellular Carcinoma Cell Secretomes by Srisomsap, Chantragan et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 437143, 18 pages
doi:10.1155/2010/437143
Research Article
ProteomicStudiesofCholangiocarcinomaand
HepatocellularCarcinomaCellSecretomes
ChantraganSrisomsap,1 PhanneeSawangareetrakul,1 PantipaSubhasitanont,1
DaraneeChokchaichamnankit,1 KhajeelakChiablaem,1 Vaharabhongsa Bhudhisawasdi,2,3
Sopit Wongkham,3,4 andJisnuson Svasti1,5
1Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok 10210, Thailand
2Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
3Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University,
Khon Kaen 40002, Thailand
4Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
5Department of Biochemistry, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand
Correspondence should be addressed to Chantragan Srisomsap, chantragan@cri.or.th
Received 1 July 2009; Accepted 28 September 2009
Academic Editor: Helen J. Cooper
Copyright © 2010 Chantragan Srisomsap et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cholangiocarcinoma(CCA)andhepatocellularcarcinoma(HCC)occurwithrelativelyhighincidenceinThailand.Thesecretome,
proteins secreted from cancer cells, are potentially useful as biomarkers of the diseases. Proteomic analysis was performed on
the secreted proteins of cholangiocarcinoma (HuCCA-1) and hepatocellular carcinoma (HCC-S102, HepG2, SK-Hep-1, and
Alexander) cell lines. The secretomes of the ﬁve cancer cell lines were analyzed by SDS-PAGE combined with LC/MS/MS. Sixty-
eightproteinswerefoundtobeexpressedonlyinHuCCA-1.Examplesincludeneutrophilgelatinase-associatedlipocalin(lipocalin
2), laminin 5 beta 3, cathepsin D precursor, desmoplakin, annexin IV variant, and annexin A5. Immunoblotting was used to
conﬁrm the presence of lipocalin 2 in conditioned media and cell lysate of 5 cell lines. The results showed that lipocalin 2 was
a secreted protein which is expressed only in the conditioned media of the cholangiocarcinoma cell line. Study of lipocalin 2
expression in diﬀerent types of cancer and normal tissues from cholangiocarcinoma patients showed that lipocalin 2 was expressed
only in the cancer tissues. We suggest that lipocalin 2 may be a potential biomarker for cholangiocarcinoma.
1.Introduction
In Thailand, cholangiocarcinoma (CCA), a malignant tumor
derived from bile duct epithelium, occurs with a high inci-
dence in tropical countries where it is associated with liver
ﬂuke (Opisthorchis viverrini) infestation and nitrosamine
ingestion [1]. CCA shows high mortality and presents
challenges in diagnosis; so prognosis for CCA patients is
r a t h e rp o o r .T h e r ei ss t i l ln e e df o rb e t t e rt u m o rm a r k e r sf o r
early diagnosis. The most widely used circulating marker
for CCA is carbohydrate antigen (CA) 19-9 [2]. However,
(CA)19-9isalsoelevatedinpancreaticcancer,gastriccancer,
and primary biliary cirrhosis and has been shown it gives
false positive results [3]. Carcinoembryonic antigen (CEA)
is the other common tumor marker used for detecting
CCA. CEA is not speciﬁc, being mainly used for colorectal
cancers, and can be elevated in other types of cancer, such as
gastrointestinal or gynecologic malignancies [4].
Diﬀerences in expression proﬁles between normal liver
and CCA tissues were studied, because CCA is contained
in liver tissue and is suggested to arise from the same
s t e mc e l l sa sH C C[ 5]. We have previously compared CCA
and HCC cell lines using proteomic techniques in order to
investigate potential CCA markers for early diagnosis [6].
Comparison of 2D-PAGE patterns for a cholangiocarcinoma
cell line (HuCCA-1) and two hepatocellular carcinoma
cell lines (HepG2 and HCC-S102) showed that cytokeratin
7 (CK7), cytokeratin 19 (CK19), an unknown proteins2 Journal of Biomedicine and Biotechnology
(U2/2), and galectin-3 were found in CCA but not in
HCC. An extension of this study investigated membrane
proteins and cytosolic proteins [7], which showed that
ten membrane proteins were found in HuCCA-1 but not
in HCC-S102, including mitogen-activated protein kinase
kinasekinase2,calgizzarin,integrinalpha-6precursor,ezrin,
and hippocalcin-like protein 1. The subproteomic approach
used here may be useful for developing potential biomarkers
for early detection of CCA. However, proteomic studies
using cell lines have limitations, since it is not known
whether the diﬀerentially expressed proteins will be present
in accessible biological ﬂuids such as plasma, serum, or urine
or not.
Cells and tissues secrete proteins into the extracellular
environment,thesecretome,whichmayreﬂectalargevariety
of pathological conditions and may be a useful source of
biomarkers. The secreted proteins are known to regulate
many biological processes. These proteins are not only
components of the extracellular matrix and biological ﬂuids
but are also involved in blood coagulation, immune defense,
signal transduction, and carcinogenesis [8]. Certain proteins
secreted from cancer cells that enter the circulatory system
can be utilized as targets for monitoring or screening for
the presence of cancer cells. The cancer secretome, such as
that from hepatocellular carcinoma [9], lung cancer [10],
breast cancer [11], and oral squamous cell carcinoma [12],
has been studied by many research groups to determine the
release of the total proteins by cancer cells. This technique
provides useful tools for the discovery of novel biomarkers,
by using a cell culture model system in which the cells
were grown in serum-free media for proteomic analysis
[13, 14]. Secretome analysis of nasopharyngeal carcinoma
(NPC)celllineshasbeenstudiedbySDS-PAGEandMALDI-
TOF MS and revealed several potential NPC protein markers
[15, 16].
Since the secretomes of cholangiocarcinoma have not
previously been reported, we have used conditioned media
to compare the secretomes of cholangiocarcinoma cell line
(HuCCA-1) with those of hepatocellular carcinoma cell lines
(HCC-S102, HepG2, SK-Hep-1, and Alexander). Expression
of proteins was studied by SDS-PAGE and LC/MS/MS,
and overexpression of proteins in HuCCA-1 was conﬁrmed
by using 1-DE and 2-DE immunodetection. Finally, the
potentialbiomarkerwasvalidatedinvarioustypesofcholan-
giocarcinoma tissues.
2.MaterialsandMethods
2.1. Sample Collection. Tissue samples were collected from
Department of Surgery, and Liver Fluke and Cholangiocar-
cinoma Research Center, Faculty of Medicine, Khon Kaen
University. Ethical clearance for the tissues was approved by
the Ethics Committee for Human Research of Khon Kaen
University (HE471214). After resection, specimens were
immediately taken to a pathologist, who sampled both the
tumor itself and adjacent normal-appearing bile duct. Both
samples were then snap-frozen in liquid nitrogen within 10
minutes of removal from the patients and stored at −80
◦C
until analysis. The details of types, ages, genders, grades, and
histopathology are shown in Table 1.
2.2. Cell Cultures. Cholangiocarcinoma cell line, HuCCA-
1 derived from bile duct tumor mass of Thai patient, was
kindly provided by Professor Sirisinha [17]a n dg r o w ni n
Ham’s F12 culture medium (Hyclone laboratories, Logan,
UT, USA), containing 15mM HEPES and supplemented
with 10% fetal bovine serum (FBS, Hyclone Laborato-
ries), 100U/mL penicillin, and 100μg/mL streptomycin and
125ng/ml amphotericin B. Hepatocellular carcinoma cells,
HCC-S102, established from Thai patient [18] was kindly
provided by Dr. Sumalee Tungpradakul and grown in RPMI
1640 (Gibco, Grand Island, NY, USA) containing 25mM
HEPES, supplemented with penicillin (100U/mL), strepto-
mycin (100μg/mL) amphotericin B (125ng/mL) (Gibco),
and 10% FBS. Another human hepatocellular carcinoma
cell line, the Alexander cell line, a human HCC-derived cell
line secreting HBsAg, originally obtained from American
Type Culture Collection (Rockville, MD, USA) was kindly
providedbyDr.MammenMammenandDr.AnandaNisalak
of the Department of Virology, the Armed Forces Research
Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
The hepatoblastoma cell line, HepG2 and hepatocellular
cell line, SK-Hep-1 were purchased from American Type
Culture Collection. The Alexander HepG2, and SK-Hep-
1 cell lines were grown in DMEM (Gibco) with 10%
FBS, 100U/mL penicillin, 100μg/mL Streptomycin, and
125ng/mLamphotericinB.Allcellsweremaintainedat37
◦C
in a humidiﬁed atmosphere, 95% air, 5% CO2 at 37
◦C.
2.3. Cell Viability Assay. After incubating the cells in com-
plete media or serum-free media for 24 hours, the numbers
ofviablecellsanddeadcellswerecountedbyusingthetrypan
blue dye exclusion method. The percentage of cell viability
was expressed as the ratio of total viable cells to the sum of
total viable and dead cells.
2.4. Harvesting Conditioned Media. To obtain culture super-
natants, approximately 3 × 107 cancer cells were grown
to 80% conﬂuence and then the cells were washed with
serum-free medium 2 times before incubation in serum-
free medium for 24 hours. After incubation, the conditioned
medium was harvested and centrifuged 800xg at 4◦Cf o r
10 minutes to remove suspended cells. The supernatant was
dialyzed against distilled water using a dialysis membrane
with molecular weight cutoﬀ 3500Da (Cellu Sep, Texas,
USA) for 48 hours and then concentrated by SpeedVac.
The concentrations of total proteins were determined by the
Bradford protein assay reagent (Bio-Rad Laboratories, CA)
[19].
2.5.SDS-PAGEofConditionedMediafromCellLines. Twenty
micrograms of conditioned media from ﬁve cell lines were
resolved on 8%–14% gradient SDS-PAGE (100 × 105 ×
0.75mm). Electrophoresis was performed in a Hoefer system
(Hoefer, Inc., San Francisco, CA, USA) at 12mA, room
temperature for 2 hours. The protein was stained withJournal of Biomedicine and Biotechnology 3
Coomassie brilliant blue R-250 (SERVA Electrophoresis
GmbH, Heidelberg, Germany).
2.6. Western Blotting and Immunodetection. Protein extracts,
separated by 12% SDS-PAGE and transferred onto nitro-
cellulose membrane (Hybond ECL, GE Healthcare, Buck-
inghamshire, UK), were probed with monoclonal antibod-
ies against NGAL (Santa Cruz Biotechnology, CA, USA).
Proteins of interest were detected using the enhanced
chemiluminescence (ECL) plus detection system, with high-
performance ﬁlm (Hyperﬁlm ECL; GE Healthcare).
2.7. Two-Dimensional Gel Electrophoresis (2-DE). 2D PAGE
was performed using the immobiline/polyacrylamide sys-
tem. Three hundred micrograms of conditioned media from
HuCCA-1 were applied by overnight in-gel rehydration
of 70mm, using nonlinear pH 3–10 IPG gel strips (GE
Healthcare).Theﬁrstdimension(IEF)wasperformedtogive
a total of 8000Vh on an IPGphor (GE Healthcare). Focused
IPG strips were equilibrated for 10 minutes in a solution
(6Murea,30%glycerol,1%SDS50mMTris-HClbuﬀer(pH
6.8), and 1% DTT), and then for an additional 10 minutes
in the same solution except that DTT was replaced by 2.5%
iodoacetamide. The IPG strips were then applied to the
second dimension 12% T SDS-PAGE (100 × 105 × 1.5mm).
After electrophoresis, proteins were visualized by Coomassie
blue R-250 staining.
2.8. Sample Preparation for SDS-PAGE Immunodetection.
Tissues were homogenized in phosphate buﬀered saline
containing 0.2mM phenylmethanesulfonylﬂuoride, 2μg/mL
pepstatin A, 1μg/mL bestatin, and centrifuged for 20
minutes at 15000 rpm. Protein content of the supernatant
was determined using the Bradford method [19]. Samples
(10μg protein) were mixed with sample buﬀer, boiled, and
applied to 15% T SDS polyacrylamide gels (100 × 80 ×
0.75mm).ElectrophoresiswasperformedinaHoefersystem
(Hoefer, Inc., San Francisco, CA, USA) at 10mA, room
temperature for 1.5 hours, followed by electroblotting of
proteins from the gel onto PVDF membranes (Immobilon-
P; Millipore, Billerica, MA, USA) at 100V for 30 minutes
at 4◦C. After blocking in 5% nonfat dry milk, membranes
were probed with 1 : 200 diluted anti-NGAL monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
repeatedly washed in 20mM Tris buﬀered saline, pH 7.6,
containing 0.1% Tween 20, and then incubated in 1 :
5000 rabbit antimouse immunoglobulin G (IgG; Dako
Cytomation, Glostrup, Denmark) for 1 hour. After washing,
the reaction was developed using the ECL plus detection
system, with high-performance ﬁlm (Hyper-ﬁlm ECL; GE
Healthcare).
2.9. Tryptic In-Gel Digestion. Protein spots were excised and
transferred to 0.5mL microfuge tubes. Fifty μLo f0 . 1 M
NH4HCO3 in 50% acetonitrile was added. The gel was
incubated 3 times for 20 minutes at 30
◦C. The solvent were
discarded and gel particles were dried completely by Speed
Vac. Reduction and alkylation were performed by swelling
the gel pieces in 50μLb u ﬀer solution (0.1M NH4HCO3,
10mM DTT and 1mM EDTA) and incubating at 60
◦Cf o r
45 minutes. After cooling, the excess liquid was removed
and quickly replaced by the same volume of freshly prepared
100mM iodoacetamide in 0.1M NH4HCO3 solution. The
reaction was incubated at room temperature in the dark for
30 minutes. The iodoacetamide solution was removed and
the gel pieces were washed with 50% acetonitrile in water,
3 times for 10 minutes each time, and the gel pieces were
completelydried.Aliquotsoftrypsin(PromegaCorporation,
WI, USA) (1μg trypsin /10μL 1% acetic acid) were prepared
and stored at −20
◦C. Fifty μL of digestion buﬀer (0.05M
Tris HCl, 10% acetonitrile, 1mM CaCl2,p H8 . 5 )a n d1μL
of trypsin were added to the gel pieces. After incubating the
reaction mixture at 37
◦C overnight, the digestion buﬀer was
removed and saved. The gel pieces were then extracted by
adding 60μL of 2% freshly prepared triﬂuoroacetic acid and
incubating for 30 minutes at 60
◦C. The extract and the saved
digestion buﬀer were ﬁnally pooled and dried.
2.10. Protein Identiﬁcation by LC/MS/MS. LC/MS/MS anal-
yses were carried out using a capillary LC system (Waters)
coupledtoaQ-TOFmassspectrometer(Micromass,Manch-
ester, UK) equipped with a Zspray ion source working in
the nanoelectrospray mode. Glu-ﬁbrinopeptide was used
to calibrate the instrument in MS/MS mode. The tryptic
peptides were concentrated and desalted on a 75μmI D×
150mm C18 PepMap column (LC Packings, Amsterdam,
The Netherlands). Eluents A and B were 0.1% formic acid
in 97% water, 3% acetonitrile, and 0.1% formic acid in 97%
acetonitrile, respectively. Six μL of sample was injected into
the nanoLC system, and separation was performed using the
following gradient: 0 minute 7% B, 35 minutes 50% B, 45
minutes 80% B, 49 minutes 80% B, 50 minutes 7% B, and
60 minutes 7% B. The database search was performed with
ProteinLynx screening SWISS-PROT and NCBI. For some
proteins that were diﬃcult to ﬁnd, the Mascot search tool
available on the Matrix Science site screening NCBInr was
used. The search parameters were set as follows: peptide
mass tolerance = 1Da; MS/MS ion mass tolerance = 1Da;
enzymesetastrypsinandallowancewassetuptotwomissed
cleavages; peptide charges were limited to 2+ and 3+. The
proteins were identiﬁed with P-values ≤ .05 and Mascot
scores >35 were considered as promising hits .
3. Results
3.1. Comparison of Secretomes from Cholangiocarcinoma and
Hepatocellular Carcinoma Cells. The secreted proteins from
conditioned media of HuCCA-1, HCC-S102, HepG2, SK-
Hep-1, and Alexander cells were resolved by SDS-PAGE and
visualized by Coomassie blue as shown in Figure 1.T h e
secreted protein patterns were enriched in the conditioned
media and showed patterns that diﬀered signiﬁcantly in each
cell line. The eﬀect of 24-hour serum starvation on the
viability of the ﬁve cancer cells cultured was tested and the
results showed that this treatment had little eﬀect on cell
viability (Figure 2).4 Journal of Biomedicine and Biotechnology
Table 1: Medical diagnosis of cholangiocarcinoma patients with tumor types and histopathology.
Sample ID Gender Age Tumor type Staging Histopathology
1F 6 2 Peripheral,
Single, Seg 7 4B
Well diﬀerentiated
adenocarcinoma,
CCA, invade
intrahepatic vein
2F 6 7
Combined,
Single, Seg 7,
Hilar, long
4A Well diﬀerentiated
tubular type, CCA
3M 6 4 Peripheral,
Single, Seg 8 4B Well diﬀerentiated
tubular type, CCA
4M 4 3 Peripheral,
Single, Seg 6 4B
Moderately diﬀ
adenocarcinoma
invade intrahepatic
vessel
5M 6 5
Peripheral,
Multiple, Seg
1-2
4A Moderately diﬀ, CCA
6M 4 6 Peripheral,
Single, Seg 6 4A
Moderately diﬀ
adenocarcinoma
invade intrahepatic
vein
7M 3 9 Peripheral,
Single, Seg 6 4B Moderately diﬀ,C C A
8F 5 6 Peripheral,
Single, Seg 6 4B
Poorly diﬀ CCA,
invade intrahepatic
vein
9M 6 7
Combined,
Single, Seg 8,
Hilar
4A Poorly diﬀ
adenocarcinoma
10 M 53 Central, Hilar,
long 3 Papillary mucinous
carcinoma
11 F 35 Peripheral,
Single 4B Papillary mucinous
cyst adenocarcinoma
12 M 49
Peripheral,
Multiple, Seg
2-4
4A Papillary mucinous
carcinoma
Because of the high sensitivity of mass spectrometry
in identifying mixtures of proteins, the stained gels were
marked and cut into 0.5 mm slices from the gel top to dye
front as shown in Figure 1. Forty-eight total gel bands were
subjected to in-gel tryptic digestion and the proteins were
identiﬁedbyLC/MS/MS.Thereare83proteinssecretedfrom
the HuCCA-1 cell line as shown in Table 2. The secreted
proteins from 4 hepatocellular carcinoma cell lines (HCC-
S102, HepG2, SK-Hep-1, and Alexander) were collected
in the form of a database, together with those of other
cell lines including lung, breast, cervical, and oral cell
lines, used in our group (manuscript in preparation). The
secreted proteins from 4 hepatocellular carcinoma cell lines
are shown in Table 1in supplementary Material available
online at doi:10.1155/2010/437143. The molecular weights
shown in Table 2 and Supplementary Table 1 are theoretical
valuesfromdatabases.Someexperimentalmolecularweights
diﬀered from theoretical values because the bands were from
SDS-PAGE, in which the proteins were denatured and found
as isozymes. From Table 2 and Supplementary Table 1,s o m e
proteins containing one matched peptide were considered
because the peptide score was greater than 35, higher than
the Mascot score of 20, which Kristiansen et al. considered
to be signiﬁcant [20]. We also manually selected only the
peptide match that had a length of at least 8 amino acids
with sequence tag of at least three amino acids to be a
good y-ion series. Relevant information on the functions of
proteinswastakenfromSwiss-ProtandNCBI.Thenproteins
were classiﬁed by their functions into various categories,
namely, chaperone/stress response, cell cycle, cytoskele-
ton/mobility, DNA replication/gene regulation, extracellular
matrix, immunological response, ion channels, metabolism,
protectionanddetoxiﬁcation,proteinsynthesisanddegrada-
tion,signaltransduction,transport/bindingproteins,tumor-
associated proteins, and unannotated/function inferred.
When the HuCCA-1 cell line is compared to the 4
hepatocellular carcinoma cell lines, all cell lines secreted
distinct protein proﬁles. We also found distinct secreted
protein proﬁles when we compared the secreted proteins to
diﬀerent types of cell lines (liver, lung, breast, cervical andJournal of Biomedicine and Biotechnology 5
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Figure 1: SDS-PAGE analysis of secretomes obtained from ﬁve cell lines. HuCCA-1, HCC-S102, HepG2, SK-Hep-1, and Alexander are
shown in order from left to right, with MW standards in the leftmost lane. Each gel was cut into 0.5mm slices, numbered as shown from the
top of the gel to the dye front. Proteins in each slice were reduced, alkylated, digested with trypsin, and subjected to LC/MS/MS analysis.
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Figure 2: Viability of cancer cells cultured in complete media or
serum-free media for 24 hours. Cell viability was determined by
trypan blue exclusion. Data are expressed as mean ± SD of from
three independent experiments.
oral). Thus, some 30%–50% proteins were expressed at the
same level in 5 cell lines, while 50%–70% proteins showed
diﬀerences in expression. Forty-nine secreted proteins were
found only in HuCCA-1 which was marked in Table 2,
including laminin 5 beta 3, heat shock 90kDa protein 1,
heat shock 70kDs protein 8 isoform 1 variant, GRP78 pre-
cursor, desmoglein-4 nephroblastoma overexpressed precur-
sor, neutrophil gelatinase-associated lipocalin (lipocalin 2,
NGAL),desmoplakin,cathepsinD,DnaJhomologsubfamily
B member 11, annexin IV variant, annexin A5, Ras-related
protein Rap-1A, RHOV protein, and rotatin isoform CRA e.
4. Validation of Potential Biomarkers
Of the overexpressed proteins found only in HuCCA-1,
15 appeared to be proteins related to cancer. 1-DE imm-
munoblottingwasusedtoverifythepresenceof4proteinsby6 Journal of Biomedicine and Biotechnology
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using speciﬁc antibodies for nephroblastoma overexpressed
precursor and neutrophil gelatinase-associated lipocalin
(lipocalin 2, NGAL). Immunodetection only conﬁrmed the
presence of lipocalin 2 (Figure 3(b)), but not the presence of
the other two proteins. Expression of lipocalin 2 was found
only in the conditioned media of HuCCA-1, but not in the
conditioned media of the other 4 cell lines (Figure 3(b)).
Furthermore, there was no expression of lipocalin 2 in the
cell lysate of any of the 5 cell lines, including HuCCA-1
(Figure 3(a)).
The 2-DE proteomic pattern of conditioned media of
HuCCA-1 with Coomassie blue staining is shown in
Figure 4(a) and 2-DE immunoblotting of the same sample
was used to detect the lipocalin 2 forms (Figure 4(b)),
revealing 4 spots with MW/pI 23.5/6.0, 23.5/6.5, 23.0/7.3,
and 22.5/8.7. These diﬀerent forms are likely to result from
posttranslational modiﬁcations.
To conﬁrm that lipocalin 2 is highly expressed in cholan-
giocarcinoma, the 12 homogenate samples from the pairs of
normal and cancer of cholangiocarcinoma tissues described
inTable 1 wereresolvedbySDS-PAGEgelsandimmunoblot-
ted with monoclonal antibody to lipocalin 2. The results
clearly showed a positive band of 23kDa in all cancer tissues
(Figure 5),with9outofthe12casesshowinghighexpression
level of lipocalin 2, while the corresponding normal tissues
were all negative.
5. Discussion
The study of the cancer secretomes by using proteomic
technology has greatly accelerated in recent years. With the
rapid progress in mass spectrometry (MS), bioinformatics,
and analytical techniques, cancer biomarker discovery has
been greatly promoted by this approach. Our present work
has investigated the cell secretomes of cholangiocarcinoma
(CCA) compared to 4 hepatocellular carcinoma (HCC)
cell lines. With each cell line, three repeat experiments
were performed by collection of the conditioned media
from CCA and HCC cell lines, followed by concentration
and precipitation by TCA/acetone. The proteins were then
run onto SDS-PAGE, gel bands excised consecutively, and
proteins analyzed by LC/MS/MS. Some bands showed low
levels of matching, some bands showed blue color, and some
were almost clear. The pattern on SDS-PAGE of secreted
proteins and the total identiﬁed proteins were diﬀered with
each cell line. When the protein expression of the HuCCA-
1 cell line is compared to the HCC cell lines, only 14, 14,
19, and 6 proteins from Alexander, HCC-S102, HepG2, and
SK-Hep-1, respectively, matched with HuCCA-1 (data not
shown).
Proteins secreted into conditioned medium may be
tumor speciﬁc and can represent potential biomarkers that
may circulate in the blood stream. Our results showed 49
distinctproteins,expressedonlyinHuCCA-1.Someinterest-
ing secreted proteins expressed only in cholangiocarcinoma
include laminin 5 beta 3, heat shock 90kDa protein 1,
heat shock 70kDs protein 8 isoform 1 variant, GRP78 pre-
cursor, desmoglein-4 nephroblastoma overexpressed precur-
sor, neutrophil gelatinase-associated lipocalin (lipocalin 2,
NGAL),desmoplakin,cathepsinD,DnaJhomologsubfamily
B member 11, annexin IV variant, annexin A5, Ras-related
protein Rap-1A, RHOV protein, and rotatin isoform CRA e.
Many of these proteins are related to cancer. For
example, laminin-5 (LAMA3, LAMB3, and LAMC2) is a
heterotrimeric glycosylated protein that belongs to th Ln
family and is formed by α3β3γ2 chains assembled with
disulﬁde bonds. Ln-5 is widely expressed in the human
body but shows diﬀerential expression in metastatic and
nonmetastatic hepatocellular carcinoma [21, 22]. Ln-5 also
plays an important role in cell migration during tumor
invasion and tissue remodeling [22], and laminin 5 γ2c h a i n
andβ3chainhavebothbeensuggestedtobeimportantinthe
invasiveness of cancer cells. Unfortunately, no commercial
antibody appears to be available for laminin 5 β3 chain;
expression of the protein could not be validated in cholan-
giocarcinoma tissues. Laminin γ2 chain exhibits aberrant
expression in a stepwise manner through diﬀerent aggressive
stages of tumor progression [23].
Nephroblastoma overexpressed (NOV) belongs to the
CCNfamilyofgenesthatencodesecretedproteinsassociated
with the extracellular matrix (ECM) and exert regulatory
eﬀects at the cellular level. NOV is likely to play a role
in cell growth regulation, in the progression and in the
metastatic potential of melanomas. The expression of this
protein appears to be associated with a higher risk of
developing metastases in Ewing’s sarcoma [24]. We found
the high expression of NOV secreted in the media of the
cholangiocarcinoma cell line.
Neutrophil gelatinase-associated lipocalin (NGAL or
lipocalin 2) is a prominent member of the lipocalin family.
It was ﬁrst isolated as a 25kda glycoprotein covalently
bound with matrix metalloproteinase-9 (MMP-9) in human
neutrophil [25]. It is a secreted acute phase protein, which is
also upregulated in multiple cancers, including breast, lung,
and pancreas. Recently lipocalin 2 has been proposed as an
early biomarker in pancreatic cancer [26].
Desmoplakin, a specialized adhesion junction protein
and the principal plaque protein of desmosomes, has been
found in various tissues including heart, skin, and meninges
[27]. The biological signiﬁcance of desmoplakin has been
recently reported in both autosomal dominant and auto-
somal recessive disorders from naturally occurring human
gene mutation. Desmoplakin was found to be abnormal in
many conditions including autoimmune blistering diseases,
epithelial malignancies, and blood vessel morphogenesis.
Desmoplakin was also found to be secreted by the cholan-
giocarcinoma cell line in our study.
Cathepsin D, the aspartic protease, is an independent
marker of poor prognosis in human breast cancer [28].
Cathepsin-D was reported to play an essential role in
multiple tumor progression steps, aﬀecting cell proliferation,
angiogenesis, and apoptosis. Another report also suggested
that cathepsin D was a key mediator in induced apoptosis
[29].Ourresultsshowedhighlyexpressionlevelsofcathepsin
D in the cholangiocarcinoma cell line. A cathepsin D-like
protein has also been reported from the gut and other tissues
of the human liver ﬂuke Opisthorchis viverrini where long-
standing infection is associated with cancer of the bile ducts16 Journal of Biomedicine and Biotechnology
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Figure 3: The western blots for immunoreactive lipocalin 2 from the lysate of ﬁve cell lines (HuCCA-1, HCC-S102, HepG2, SK-Hep-1, and
Alexander) (a) and ﬁve conditioned media samples (b).
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Figure 4: Two-dimensional gel electrophoresis of conditioned media from HuCCA-1 stained with Coomassie Blue R-250 (a) and
immunoblot labeled with the antibody to lipocalin 2 (b). The pI and MW of spot numbers 1, 2, 3, and 4 were approximately 6.0/23.5,
6.5/23.5, 7.3/23, and 8.7/22.5 respectively.
or cholangiocarcinoma [30]. This protein was also found in
the excretory and secretory products of cultured adult ﬂukes,
indicating a role in host-parasite relationships.
The annexins are family of calcium-regulated
phospholipid-binding proteins with diverse roles in cell
biology. There are 12 human annexin subfamilies (A1–A11
and A13) that have been found to have various intra- and
extracellular roles in a range of cellular processes such as
cell signalling, ion transport, cell division, and apoptosis
[31, 32]. Individual annexins have been implicated in
tumour development and progression. Annexins A1, A2,
and A5 interact with cytoskeletal proteins. Annexin A1 also
has a role in controlling the inﬂammatory response while
annexin A2 is present on the external surface of endothelial
cells. Annexin A2 and annexin A4 appeared to be potential
markers of interest for diagnosis of colorectal cancer [33].
The present studies showed that annexin A1, annexin A2,
annexin IV variant, and annexin A5 were expressed in the
cholangiocarcinoma cell line.
The presence of the proteins nephroblastoma over-
expressed precursor and neutrophil gelatinase-associated
lipocalin (lipocalin 2, NGAL) was validated in the cell lysates
and conditioned media from all 5 cells by using speciﬁc
antibodies. Lipocalin 2 was found to be clearly expressed
in only conditioned media. Then 2-DE immunoblot-
ting of the conditioned media showed the expression
of lipocalin 2 as 4 spots at MW/pI 23.5/6.0, 23.5/6.5,
23.0/7.3, and 22.5/8.7 (Figure 4(b)). The posttranslation
modiﬁcation of the lipocalin 2 has not been reported
yet and further studies will be needed to provide more
information.
Finally, we veriﬁed the expression of lipocalin 2 in 12
homogenate samples from the pairs of normal and cancer
tissues from cholangiocarcinoma patients. The lipocalin 2
antibody clearly detected a band of 23kDa in all cancer
tissues, while the pairs of normal tissues were all negative. Of
the cancer tissues, 9 out of 12 cases showed high expression
levels of lipocalin 2. However, since the cases studied here
were in the late stage (grade 3-4) of cancer, it is of interest
to see if tissues at the early stages of cholangiocarcinoma
show lipoclain 2 expression. Further studies will investigate
the expression of lipocalin 2 in diﬀerent types and stages ofJournal of Biomedicine and Biotechnology 17
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Figure 5: 1-DE patterns of the pairs of normal and cancer tissues from 12 cholangiocarcinoma patients. Details of the patients are shown
from Table 1. The proteins were separated in 15% SDS-PAGE and detected using by immunoblotting with antibody to lipocalin 2.
cholangiocarcinoma in order to understand its relationship
to grades and types of cancer.
6. Conclusion
Proteomic techniques have been used to compare the secre-
tomes or proteins secreted into the external environment,
cholangiocarcinoma,andhepatocellularcarcinomacelllines.
Distinct proteins were found, in particular lipocalin 2, which
may have potential value as a biomarker for cholangiocarci-
noma.
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